Flushing and gastrointestinal tolerability events in relapsing remitting multiple sclerosis (RRMS) patients treated with oral BG-12 dimethyl fumarate) in the phase 3 DEFINE and CONFIRM trials

被引：0
|
作者：
Selmaj, K. [1 ]
Gold, R. [2 ]
Fox, R. J. [3 ]
Havrdova, E. [4 ]
Giovannoni, G. [5 ]
Pace, A.
Novas, M.
Meltzer, L.
Hotermans, C.
Viglietta, V.
Phillips, J. T. [6 ]
机构：
[1] Med Univ Lodz, Lodz, Poland
[2] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany
[3] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44106 USA
[4] Charles Univ Prague, Prague, Czech Republic
[5] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[6] Baylor Inst Immunol Res, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2013年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：221 / 221
页数：1
相关论文
共 50 条
  • [41] Health-related quality of life in relapsing remitting multiple sclerosis (RRMS) patients treated with placebo or BG-12 (dimethyl fumarate): comparison with other medical conditions
    Sarda, S.
    Phillips, G.
    Gaebler, J. A.
    Kurukulasuriya, N. C.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 290 - 290
  • [42] Three-year follow-up of oral BG-12 (dimethyl fumarate) treatment in relapsing remitting multiple sclerosis (RRMS): integrated magnetic resonance imaging (MRI) outcomes from DEFINE, CONFIRM, and ENDORSE
    Miller, D. H.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    MacManus, D.
    Yousry, T.
    Zhang, R.
    Yang, M.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 461 - 462
  • [43] Safety and Tolerability of BG-12 (Dimethyl Fumarate) in Patients with Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of Phase 2 and 3 Placebo-Controlled Studies
    Phillips, J. Theodore
    Fox, Robert
    Gold, Ralf
    Havrdova, Eva
    Kappos, Ludwig
    Raghupathi, Kartik
    Yuan, Huixing
    Viglietta, Vissia
    Sheikh, Sarah
    Dawson, Katherine
    Novas, Mark
    Sweetser, Marianne
    Selmaj, Krzysztof
    NEUROLOGY, 2013, 80
  • [44] THE COST EFFECTIVENESS OF BG-12 (DIMETHYL FUMARATE) FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Su, W.
    Walker, A.
    Sarda, S.
    Kansal, A. R.
    Vicente, C.
    Deniz, B.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [45] Pharmacology and clinical efficacy of dimethyl fumarate (BG-12) for treatment of relapsing-remitting multiple sclerosis
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2014, 10 : 229 - 239
  • [46] Long-term safety and tolerability of oral BG-12 (dimethyl fumarate) in relapsing-remitting multiple sclerosis: interim results from ENDORSE
    Phillips, J. T.
    Fox, R. J.
    Selmaj, K.
    Raghupathi, K.
    O'Gorman, J.
    Novas, M.
    Sweetser, M. T.
    Viglietta, V.
    Dawson, K. T.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 517 - 518
  • [47] BG-12 (Dimethyl Fumarate) Treatment for Relapsing-Remitting Multiple Sclerosis (RRMS) Increases the Proportion of Patients Free of Measured Clinical and Neuroradiologic Disease Activity in the Phase 3 Studies
    Havrdova, Eva
    Gold, Ralf
    Fox, Robert
    Kappos, Ludwig
    Phillips, J. Theodore
    Zhang, Annie
    Kurukulasuriya, Nuwan
    Sheikh, Sarah
    Viglietta, Vissia
    Dawson, Katherine
    Giovannoni, Gavin
    NEUROLOGY, 2013, 80
  • [48] An integrated analysis of safety and tolerability of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis from phase 2 and 3 placebo-controlled studies
    Phillips, J. T.
    Fox, R. J.
    Gold, R.
    Havrdova, E.
    Kappos, L.
    Raghupathi, K.
    Yuan, H.
    Viglietta, V.
    Sheikh, S. I.
    Dawson, K. T.
    Novas, M.
    Sweetser, M. T.
    Selmaj, K.
    JOURNAL OF NEUROLOGY, 2013, 260 : S75 - S75
  • [49] THE BUDGET IMPACT OF INTRODUCING BG-12 (DIMETHYL FUMARATE) FOR TREATMENT OF RELAPSE-REMITTING MULTIPLE SCLEROSIS (RRMS) IN CANADA
    Dorman, E.
    Kansal, A. R.
    Sarda, S.
    VALUE IN HEALTH, 2013, 16 (07) : A620 - A620
  • [50] Effects of BG-12 on Magnetic Resonance Imaging (MRI) Endpoints in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Data From the Phase 3 CONFIRM Study
    Miller, David
    Fox, Robert
    Phillips, J. Theodore
    Kita, Mariko
    Hutchinson, Michael
    Havrdova, Eva
    Zhang, Ray
    Viglietta, Vissia
    Dawson, Katherine
    NEUROLOGY, 2012, 78
12345